Skip to main content
Clinical Trials/KCT0002599
KCT0002599Recruiting未知

The effect of Mirabegron for the double-J stent discomfort: Randomized, prospective case-control study.

Korea University Ansan Hospital0 sites100 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
20(Year) to o Limit (—)
Sex
All

Inclusion Criteria

  • Patients to be undergone double J stent indwelling after flexible or rigid ureteroscopic stone removal.
  • 1. =20 years
  • 2. Undergoing unilateral retrograde double-J (DJ) stent (6Fr) placement planned for 5-28 days indwelling (only after ureteroscopic procedure, retrograde intrarenal surgery)

Exclusion Criteria

  • 1. After percutaneous nephrolithotomy, open or laparoscopic ureterolithotomy
  • 2. Presence of ureteral stone
  • 3. Renal insufficiency (serum Cr > 1.7)
  • 4. Febrile UTI (fever > 38°, evidence of urinary infection)
  • 5. Pregnancy or breast feeding
  • 6. Solitary kidney
  • 7. Hypersensitivity to mirabegron
  • 8. Current use of any alpha-blocker, calcium-channel blocker, corticosteroid, Anti-muscarinic agents (within 4 weeks)
  • 9. Moderate or severe cardiovascular or cerebrovascular disease
  • 10. Hepatic dysfunction (>2 x normal LFT)
  • 11. Prior history of pelvic surgery or irradiation
  • 12. Prior history of TURBT or prostate surgery
  • 13. Significant active medical illness which in the opinion of the investigator would preclude protocol treatment
  • 14. Genetic disorder such as Galatose intolerance, Lapp Lactase deficiency, Glucose-Galactose malabsorption

Investigators

Similar Trials